“Cost-Per-Responder Analysis of Tralokinumab Versus Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis in the US and Canada”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 1, Jan. 2024, p. s317, https://doi.org/10.25251/skin.8.supp.317.